flurbiprofen has been researched along with Bleeding in 2 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-eight coronary care units (CCUs) in France participated in this double-blind, placebo-controlled, multicentre study to assess the efficacy of flurbiprofen, a non-steroidal anti-inflammatory agent (NSAID) with potent anti-platelet activity (PAA), in the prevention and recurrence of myocardial infarction (MI) and reocclusion of the infarct-related artery (IRA) in patients successfully treated for acute MI by thrombolysis and/or coronary angioplasty within 6 h of onset of symptoms." | 9.07 | Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. ( Brochier, ML, 1993) |
| "Thirty-eight coronary care units (CCUs) in France participated in this double-blind, placebo-controlled, multicentre study to assess the efficacy of flurbiprofen, a non-steroidal anti-inflammatory agent (NSAID) with potent anti-platelet activity (PAA), in the prevention and recurrence of myocardial infarction (MI) and reocclusion of the infarct-related artery (IRA) in patients successfully treated for acute MI by thrombolysis and/or coronary angioplasty within 6 h of onset of symptoms." | 5.07 | Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. ( Brochier, ML, 1993) |
| " The present study focused on exploring the genetic etiology of idiopathic hyper sensitivity to coumarin anticoagulants in a patient who presented with multiple bleeding episodes and supra-elevated International Normalized Ratios." | 3.79 | Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity. ( Deb, R; Dube, D; Nahar, R; Parakh, R; Saxena, R; Singh, TP; Verma, IC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nahar, R | 1 |
| Dube, D | 1 |
| Parakh, R | 1 |
| Deb, R | 1 |
| Saxena, R | 1 |
| Singh, TP | 1 |
| Verma, IC | 1 |
| Brochier, ML | 1 |
1 trial available for flurbiprofen and Bleeding
| Article | Year |
|---|---|
Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Double-Blind Method; Female; Flurbiprofen; Hemorrhage; | 1993 |
1 other study available for flurbiprofen and Bleeding
| Article | Year |
|---|---|
Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity.
Topics: Acenocoumarol; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Base Sequence; Binding Sites; Coumarin | 2013 |